News Home testing devices for sleep apnoea backed for NHS use Five home-testing devices for obstructive sleep apnoea hypopnoea syndrome (OSAHS), a potentially dangerous condition affecting 2.5 million adults in the UK, have been reco
R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face